In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
News|Podcasts|March 10, 2026
ACT Brief: Bayesian Shifts Regulatory Culture, Quality Tolerance Limits Drive Risk Management, CBER Leadership Changes
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore how Bayesian methods are reshaping FDA interactions and trial design, quality tolerance limits are becoming operational guardrails in risk-based quality management, and leadership transitions at the FDA's Center for Biologics Evaluation and Research signal evolving regulatory priorities.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In the final segment of his video
interview , David Morton, PhD, director of biostatistics at Certara, discussed how FDA guidance is encouraging adaptive, data-driven trial designs. Early engagement on priors and external controls fosters collaboration, moving away from rigid designs toward probabilistic decision-making, with a hybrid ecosystem emerging where Bayesian approaches become standard in appropriate contexts. - An analysis of quality tolerance
limits across nearly 580 trials reveals practical implementation patterns for risk-based quality management. With 39% of studies exceeding tolerance thresholds and breaches often occurring in specific windows, quick triage and documented decisions proved effective, with median breach duration of two snapshots allowing rapid restoration of compliance. - Vinay Prasad is stepping down as
head of the FDA's Center for Biologics Evaluation and Research, returning to UCSF after implementing major reforms including the two-to-one pivotal trial requirement and a risk-stratified framework for ultra-rare diseases. His tenure saw record approvals but also controversial decisions, reflecting ongoing tension between accelerating pathways and maintaining trial rigor.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trending on Applied Clinical Trials Online
1
Syneos Health, Optum Partner on Adaptive Clinical Development Model
2
Where AI Governance in Clinical Development Falls Short
3
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
4
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
5